Can Chronic-Phase Chronic Myeloid Leukemia Patients Achieve Optimal and Durable Responses after Two Failed TKI Treatments? Real-World Evidence Data

Acta Haematol. 2019;142(2):61-63. doi: 10.1159/000496449. Epub 2019 May 21.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Dasatinib
  • Humans
  • Leukemia, Myeloid, Chronic-Phase*
  • Protein Kinase Inhibitors

Substances

  • Protein Kinase Inhibitors
  • Dasatinib